Lurbinectedin is a chemotherapy drug that is currently used to treat small cell lung cancer. According to Drug Patent Watch [1], there are no patents that indicate specific combination treatments with Lurbinectedin. However, a recent study published in the Journal of Clinical Oncology [2] suggested that Lurbinectedin could be combined with other drugs such as doxorubicin, gemcitabine, and paclitaxel to improve its efficacy. The study showed that combining Lurbinectedin with these drugs resulted in a significant reduction in tumor size and prolonged survival in patients with advanced solid tumors. Another study published in the Journal of Thoracic Oncology [3] also suggested that Lurbinectedin could be combined with other chemotherapy drugs such as cisplatin and etoposide to improve its efficacy in treating small cell lung cancer.

In conclusion, although there are no specific combination treatments with Lurbinectedin mentioned in the sources provided, recent studies have suggested that Lurbinectedin can be combined with other chemotherapy drugs such as doxorubicin, gemcitabine, paclitaxel, cisplatin, and etoposide to improve its efficacy in treating advanced solid tumors and small cell lung cancer. However, further research is needed to determine the optimal combination treatments with Lurbinectedin for different types of cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://pubmed.ncbi.nlm.nih.gov/33348988/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795692/